Drug-Eluting Stents Often Used In Patients At Low Risk Of Restenosis

The chief advantage of drug-eluting stents (DES) over bare-metal stents is that they significantly reduce the risk of restenosis. The chief disadvantages of DES are their greater cost and the requirement for prolonged dual antiplatelet therapy after DES implantation. In a study published in Archives of Internal Medicine,  Amit Amin and colleagues analyzed data from 1.5…

Click here to continue reading…

Meta-Analysis Compares Drug-Eluting and Bare-Metal Stents for Primary Angioplasty

A new meta-analysis comparing drug-eluting stents (DES) and bare-metal stents (BMS) in patients with myocardial infarction has provoked opposing take-away messages from an author of the study and an editorialist. The authors emphasize the reduction in target-vessel revascularization (TVR) associated with DES, but the editorialist focuses on several potential DES weaknesses suggested by the study….

Click here to continue reading…